Sartorius Stedim Biotech rose by almost 6% on the Paris Bourse on Thursday following the publication of its preliminary results for fiscal 2022, which were still considered "solid".

The biopharmaceutical supplier posted sales of €3.49 billion last year, representing organic growth of 13.2% at constant exchange rates.

Including acquisitions, growth reached 15.1%.

Sartorius Stedim's recurring Ebitda was €1.22 billion, compared with €1.03 billion in 2021, representing a margin of 35%, down from the 35.8% announced for fiscal 2021.

After two "exceptional" years due to the pandemic, Sartorius Stedim reports a "normalization" of demand, in line with its forecasts.

For 2023, Sartorius Stedim expects sales growth "in the low single-digit percentage range" and "in the mid-to-high single-digit percentage range", without taking into account Covid-19 pandemic-related activities.

Sartorius Stedim's current EBITDA margin is expected to be approximately at the same level as the previous year, given the still significant uncertainties surrounding the global political and economic situation.

Its forecasts for 2025 are essentially confirmed, although the sales target has been revised upwards to around 4.4 billion euros, due to price trends in the face of inflation.

Copyright (c) 2023 CercleFinance.com. All rights reserved.